Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-01-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 4th Board of Directors of Yunnan Shengwu Valley Pharmaceutical Co., Ltd. It details meeting attendance, voting results on specific proposals, and references related announcements on the stock exchange website. The content focuses on board meeting decisions and procedural details rather than financial results or reports. There is no indication of financial statements or comprehensive financial data. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-01-19 Chinese
独立董事关于第四届董事会第十三次会议相关事项的独立意见公告
Board/Management Information Classification · 95% confidence The document is an announcement from independent directors regarding their opinion on matters discussed at the 13th meeting of the 4th board of directors. It includes details about the approval process and voting related to a proposal on the delay and modification of a share increase plan by controlling shareholders and related parties. The content focuses on board meeting opinions and governance matters rather than financial results, audit, or shareholder voting outcomes. It is not a full annual report, audit report, earnings release, or voting results announcement. The document fits best under Board/Management Information (MANG) as it relates to board meeting opinions and governance decisions.
2023-01-19 Chinese
关于召开2023年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2023 first extraordinary general meeting (临时股东大会) of the company. It details the meeting date, voting methods, attendees, agenda items, registration methods, and other procedural information. There is no financial data, no report attached or published, and no transcript or results of the meeting. The document is a formal announcement of a shareholders meeting, not the meeting materials or results themselves. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-01-19 Chinese
第四届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the ninth meeting of the fourth Supervisory Board of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. It references another announcement for details on a specific agenda item but does not contain financial statements or detailed financial data. The document is a meeting resolution announcement rather than a full report or financial filing. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a Board/Management Information announcement about changes in directors or senior management, but rather a Supervisory Board meeting resolution. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length is short and it is an announcement of meeting resolutions, not a full report or presentation.
2023-01-19 Chinese
关于控股股东、实际控制人实施稳定股价方案的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding a stock price stabilization plan implemented by the controlling shareholder and actual controller. It details the conditions triggering the plan, the measures to be taken (such as share repurchases and stock increases), and the commitments and constraints related to these measures. The document does not contain financial statements or detailed financial performance data but rather focuses on corporate actions related to shareholding and stock price management. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about capital market activities, specifically about share repurchase and shareholding changes to stabilize stock price. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is a substantive announcement, not merely a report publication notice or certification. Hence, CAP is the most appropriate classification with high confidence.
2023-01-19 Chinese
关于触发稳定股价措施启动条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company regarding the triggering of conditions to initiate stock price stabilization measures. It discusses the company's stock repurchase and shareholding policies to maintain stock price stability, referencing prior approvals and regulatory compliance. The document is short (1309 characters) and serves as a notification about the activation of a pre-established stock price stabilization plan rather than a detailed financial report or a full capital/financing update. It does not contain financial statements or detailed financing data but rather informs shareholders and the market about the triggering event and planned subsequent announcements. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including stock repurchase and shareholding actions.
2023-01-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.